Arresting the Autoimmune Cascade

Genetically-targeted oral HLA inhibitor impacting autoimmune diseases of high unmet need

Aurimi designs novel drugs to selectively block HLA-driven autoantigen response as the root cause of autoimmunity.

Type 1 diabetes is an autoimmune disease that affects more than 1.6 million people worldwide with 60,000 or more diagnosed in the US each year.

Many patients are children diagnosed at a very young age needing life-long daily insulin injections

Oral HLA-specific Drug to Knock Out Autoimmune Response

AMT-002 is designed as an oral, daily therapy for T1D patients known to have the genetic allele HLA-DQ8.

Studies of AMT-002 have shown the drug to be safe with a novel mechanism of selectively blocking autoantigens that cause autoimmunity

( OUR PROGRAM )

AMT-002

Majority of patients with Type 1 diabetes have the HLA-DQ8 gene that leads to presentation of insulin and related peptides as autoantigens.

We have completed chronic toxicity and pharmacokinetic studies to show its safety and ease of oral delivery.

AMT-002 studied in Phase 1 clinical trials in healthy subjects and T1D patients to show favorable safety and drug pharmacokinetics

Peter Gottlieb, MD

Founder, CMO, CEO
Board Member

Nandan Padukone, PhD, MBA

President, Board Member

Jessica Beaver, PhD

Head, Regulatory Affairs

Lindsey Brinton, PhD

Head, Clinical Operations